|Systematic (IUPAC) name|
|Mol. mass||296.407 g/mol|
|Metabolism||Hepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)|
|Half life||Approximately 40 hours|
|Excretion||Renal, 80% (of which 49% unchanged)|
Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV—nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy—and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2007, it is the most recent 5-HT3 antagonist to enter clinical use.
- ↑ 1.0 1.1 De Leon A (2006). "Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting". Proceedings (Baylor University. Medical Center) 19 (4): 413–6. PMID 17106506. Full text at PMC: 1618755.
- ↑ Aloxi® Oral Capsule. MGI Pharma (2007). Retrieved on 2007-05-16.
Antiemetics and antinauseants (A04)
|Serotonin (5-HT3) antagonists||Ondansetron • Granisetron • Tropisetron • Dolasetron • Palonosetron|
|Other||Scopolamine • Cerium oxalate • Chlorobutanol • Metopimazine • Cannabinoids (Dronabinol, Nabilone) • NK1 receptor antagonist (Aprepitant, Fosaprepitant)|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies